On September 11, Ginatech, a subsidiary of AO Pharmasynthez, launched a 1 billion rouble production line for bronchodilator drugs at its Irkutsk plant, the parent company’s press service told GxP News.
“We invested about 1 billion rubles. Twelve drugs have currently passed clinical trials and we are in the registration process. In total, we will produce approximately 25 drugs. In 2026-2027, we will be able to cover about 25% of the market,” said Vikram Punia, President of the Pharmasyntez Group, at the launch ceremony.
The new workshop will produce drugs for treating respiratory diseases—bronchial asthma and chronic obstructive pulmonary disease (COPD). At full capacity by the end of 2027, production volume will reach 125 million capsules and 3 million aerosols annually. Ginatech intends to focus on the Russian market but expects to expand abroad over time.
Pharmsynthez had earlier announced plans to launch several new plants and workshops in 2025 in Moscow, the Kaluga region, Irkutsk, Ussuriysk, Tyumen, and Bratsk.
The Pharmasyntez Group develops and manufactures drugs for oncology, hematology, endocrinology, immunology, and cardiology, as well as treatments for orphan, hormonal, infectious, autoimmune, and cardiovascular diseases. Its annual production output exceeds 100 million packages.
